News

Record Revenue and Future Expansion of JCET Group in 2024

Record Revenue and Future Expansion of JCET Group in 2024

JCET Group Achieves Record Revenue in 2024

In an impressive display of growth, JCET Group announced exceptional financial results for the year 2024. The company has established itself as a leader in integrated circuit (IC) back-end manufacturing and technology services, achieving record revenue figures that highlight its resilience and commitment to innovation. Reports reveal that JCET’s revenue soared to RMB 35.96 billion for the entire year, showcasing a remarkable 21.2% increase year-on-year.

Q4 Financial Highlights of JCET Group

In the fourth quarter alone, JCET achieved RMB 10.98 billion in revenue, marking a substantial increase of 19.0% from the previous year and 15.7% from the preceding quarter. This milestone sets a new quarterly record in the company's history, exemplifying JCET's strong market position.

Significant Year-on-Year Increases

The net profit attributable to parents reached RMB 1.61 billion, which represents an increase of 9.4% compared to the previous year. Cash flow from operations for the entire year tallied at RMB 5.83 billion, while JCET recorded free cash flow of RMB 1.26 billion. Earnings per share stood at RMB 0.9, further solidifying JCET's financial stability and growth trajectory.

Strategic Business Overview

In its quest for sustained growth in 2024, JCET focused on leveraging its core applications and enhancing customer loyalty. The company prioritized innovations in advanced packaging technologies, intending to transition towards advanced manufacturing solutions. Despite encountering short-term cost pressures, JCET is optimistic regarding its long-term growth prospects driven by technological innovation.

Growth in Key Business Segments

Notably, revenue from the computing electronics segment rose by 38.1% year-on-year. Meanwhile, the automotive sector saw a year-on-year increase of 20.5%, attributed to breakthroughs in advanced driver-assistance systems (ADAS) and electrification technologies. These advancements underscore JCET’s commitment to meeting the evolving demands of leading industry players.

Focus on Technological Innovation

JCET's dedication to driving innovation is evident in its substantial investment in research and development. The company allocated RMB 1.72 billion to R&D in 2024, reflecting a 19.3% increase year-on-year. This commitment has led to the filing of 587 new patent applications, expanding the company's portfolio to a total of 3,030 patents. Such advancements ensure that JCET maintains a competitive edge in the semiconductor industry.

Notable Projects and Developments

In 2024, JCET ramped up capital expenditures to solidify its market position. The acquisition of an 80% stake in SanDisk in Shanghai represents a significant step forward for the company. Moreover, JCET's advanced manufacturing base in Jiangyin is now operational, offering services for high-performance chip production. A new facility specializing in automotive chip back-end manufacturing is expected to begin operations soon, signaling JCET's expansion into the high-end automotive electronics market.

CEO Insights on Future Direction

Mr. Li Zheng, CEO of JCET, expressed confidence in the company's strategic direction. By focusing on core applications and key markets, JCET is transitioning toward high value-added segments, achieving significant milestones in 2024. In light of the ongoing shifts in the semiconductor market, JCET remains committed to technological advancements and industry collaboration, positioning itself for continued growth.

Frequently Asked Questions

What was JCET Group's revenue for 2024?

JCET Group achieved record-high revenue of RMB 35.96 billion for the year 2024.

How did JCET's Q4 2024 performance compare to previous quarters?

In Q4 2024, JCET's revenue reached RMB 10.98 billion, which was a 19.0% increase compared to the same quarter the previous year.

What is the company's focus moving forward?

JCET aims to leverage technological innovations and enhance customer loyalty while expanding into high-end markets, particularly in automotive electronics.

What investments has JCET made in R&D?

In 2024, JCET invested RMB 1.72 billion in R&D, leading to the filing of 587 new patent applications and enhancing its competitive edge.

How is JCET expanding its operational capacity?

JCET has ramped up capital expenditures and completed the acquisition of an 80% stake in SanDisk while opening a new advanced manufacturing base to support high-performance chip production.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Brands Must Choose: Cost or Value Leadership?

Updated Category News Views 6

Navigating the Business Jungle: Strategic Choices Unveiled If you've ever found yourself tangled in a web of corporate doublespeak, then you'll nod along with this: all those lofty brand management strategies often boil down to a fight over dollars or dizzying customer satisfaction. What's the winning play? According to Info-Tech Research Group, it's about firmly standing...

Continue Reading
Rise Treatment Center Launches in Vegas for Teens

Updated Category News Views 6

Las Vegas Debuts Rise Adolescent Treatment Center Imagine being a parent in Las Vegas, staring at the daunting task of finding genuine help for your teenage kid just entering those rebellious years. The choices usually feel sparse and lacking. But on August 13, 2026, a shimmer of hope illuminated the landscape with the opening of Rise Adolescent Treatment Center. It’s a...

Continue Reading
Microplastics Webinar: Navigating Complex Regulations

Updated Category News Views 7

Buckle up, folks. The plastics debate is where regulatory battles and environmental concerns collide, and big changes are on the horizon. Let's talk about Bergeson & Campbell's latest shindig: "Plastics and Policy: Microplastics, EPR, and Other Emerging Trends"—a free-to-join webinar aiming to lift the lid on what's brewing beneath the surface of regulatory waters. The...

Continue Reading
Lincoln Educational Services Faces Securities Fraud Suit

Updated Category News Views 4

A Storm Brews Over Lincoln Educational Services You know, there's nothing quite like the stink of a good mess in the markets, and Lincoln Educational Services Corporation has found itself knee-deep in one. The buzz is all about some securities fraud allegations that could rope in a bunch of investors who got the short end of the stick. It’s lawsuits like these that make...

Continue Reading
Unicycive's Legal Turmoil: Opportunity for Investor Action

Updated Category News Views 5

Unicycive's Legal Headache: What's Brewing? Here we go again, folks. If you're holding shares of Unicycive Therapeutics, Inc. (UNCY), buckle up because it's looking like a storm's on the horizon. The Law Offices of Howard G. Smith have dropped the news that shareholders can step up to lead a securities fraud class action lawsuit against the company. That chance to be part...

Continue Reading
NSF Backs New Space Projects: Cooling & Drug Delivery

Updated Category News Views 7

You know, every time we think we're at the edge of current science, space reminds us how little we actually know. From the International Space Station up there in low Earth orbit, fresh experiments are kicking off to change what we understand about electronics cooling and drug delivery. It's a classic scenario of reaching for the stars to help us out back here on Earth....

Continue Reading
Dr. David Lifschutz Honored for Psychiatry Innovation

Updated Category News Views 7

Recognizing a Legacy in Mental Wellness Under the glare of recognition's spotlight, Dr. David H. Lifschutz steps into an exclusive circle of elite professionals. He's been acknowledged as a Pinnacle Lifetime Member by The Inner Circle for his remarkable contributions to psychiatry and mental health care. This ain't just any pat on the back. It's a badge of honor stitched...

Continue Reading
NORD Honors Innovators Shaping Rare Disease Treatment

Updated Category News Views 9

Saluting the Trailblazers in Rare Disease Space Alright, let's cut to it. In a world flooded with more rare diseases than most of us can count, about 10,000 of them, only a measly 5% have any kind of approved treatment. The National Organization for Rare Disorders (NORD) is out here celebrating the folks who dare to change that bleak outlook. With the 2026 Rare Impact...

Continue Reading
illycaffè's B Corp™ Recertification Reflects Bold Commitment

Updated Category News Views 6

illycaffè Hits Milestone with B Corp™ Recertification In an era where corporate responsibility isn't just fodder for feel-good presentations, illycaffè has proven it’s not just paying lip service to the idea. The Italian coffee titan has secured its B Corp™ recertification under snazzier, sharper V2 standards. This isn't just a shiny sticker to slap on marketing...

Continue Reading
Starr Conspiracy Unveils AI Tool for B2B Tech Firms

Updated Category News Views 6

AI-Driven Insight in Minutes: A Game Changer for B2B Hold onto your hats, because The Starr Conspiracy just lit a fire in the B2B tech world with its latest offering—Battle Card Builder. This free tool cranks out competitive intelligence in no time, literally about four minutes. Geared specifically for B2B tech marketing and sales teams, it combines decades of know-how...

Continue Reading

Top 5 Most Recently Viewed Articles

60 Degrees Pharmaceuticals Launches Study on Tafenoquine Treatment

Updated Category News Views 121

Introduction to B-FREE Chronic Babesiosis Study 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW), a dedicated pharmaceutical company focused on developing innovative treatments for vector-borne diseases, is pleased to announce the opening of the clinical site for its B-FREE Chronic Babesiosis Study. Conducted at the prestigious Cohen Center for Recovery from Complex...

Continue Reading
Revolutionizing Snack Time: A Healthier Noodle Innovation

Updated Category News Views 86

Transforming Snacking with Innovative Noodle Creation In today's fast-paced lifestyle, finding healthy snack options can be a challenge. One inventor, passionate about delivering nutritious alternatives, embarked on a mission to rethink how we view noodles as snacks. The result is a groundbreaking creation known as the ELECTRIC NOODLES. This inventive snack item provides...

Continue Reading
New Pacific Metals Enhances Financing Flexibility with New Shelf

Updated Category News Views 181

Introduction to New Pacific Metals Corp New Pacific Metals Corp. is an innovative exploration and development company that specializes in precious metals. With its headquarters in Canada, New Pacific focuses on transforming its significant projects into productive mining operations, aiming to hold a strong position in the market. New Base Shelf Prospectus Filed Recently,...

Continue Reading
ALK's ITULAZAX® Approved for Pediatric Allergy Treatment in Europe

Updated Category News Views 307

ALK's ITULAZAX® Approved for Pediatric Allergy Treatment ALK (ALKB.DC / OMX: ALK B) has exciting news! The recent approval of its tree pollen sublingual allergy immunotherapy tablet, ITULAZAX®, for children and adolescents aged five to 17 marks a significant step forward in allergy treatment options available in Europe. Health authorities across 17 EU countries have...

Continue Reading
SelectQuote Faces Class Action Lawsuit Amid False Claims Issues

Updated Category News Views 164

Overview of the Lawsuit Against SelectQuote, Inc. Recently, a significant securities class action lawsuit has been initiated concerning SelectQuote, Inc. (SLQT), bringing to light serious allegations against the company. This litigation unfolds as a result of claims surrounding potential misconduct that raises concerns about the integrity of its business operations....

Continue Reading